[2021] Fluorouracil (5FU) Market Comprehensive Analysis of Business Models, Key Strategies snd Global Industry Size, Share, Trends and Growth Analysis 2027

SEATTLE, April 14, 2021, (PHARMIWEB) — Overview:

Fluorouracil is an antimetabolite and pyrimidine synthetic compound, which is viably utilized in cancer therapy. Fluorouracil is first line chemotherapy drug utilized for therapy of cancer patients.

Covid-19 Impact:

The Covid-19 has spread all through the world and hampered development of a few business sectors across the globe. According to National Cancer Institute, U.S., some cancer treatments, for example, chemotherapy can bring down the immunity of the cancer patient and may expand danger of COVID-19 in them.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4246

Drivers:

Approval and launch of combination treatments is expected to propel growth of the fluorouracil (5FU) market. For instance, in 2016, Shire plc announced that the European Commission has granted approval to ONIVYDE for treatment of metastatic adenocarcinoma of pancreas in combination with 5-fluorouracil and leucovorin in treatment of adults. Similarly, in June 2020, the U.S. Food Drug and Administration approved Keytruda (Merck) with fluorouracil, leucovorin and oxaliplatin as a first line drug treatment for colorectal cancer.

Moreover, launch of new products is also expected to aid in growth of the market. For instance, in 2019, Accord Healthcare announced that they have launched a fluorouracil injection in Australia.

Opportunities:

Initiatives to offer cancer medicines at low cost is expected to offer lucrative growth opportunities for players in the fluorouracil (5FU) market.  Fluorouracil is given foundationally for treating anal, breast, stomach, and pancreatic cancers and regulated topically in the therapy of Bowen’s disease and skin disease. As per the World Health Organization, fluorouracil is the best and most secure medication for cancer treatment. As per the International Medicinal Product Price Guide, the discount cost of fluorouracil in non-industrial nations is between US$ 1.18 to US$ 3.40 per 500 mg vial.

Moreover, R&D in Fluorouracil is also expected to aid in growth of the market. For instance, in 2016, the University Of Michigan Rogel Cancer Center completed its study on Gemcitabine, Infusional 5–Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers.

Restraints:

High cost of drugs is expected to hinder the growth of fluorouracil (5FU) market. For instance, the cost of 5–fluorouracil topical cream 0.5 is around US$ 1,253 for 30 gm in the U.S.

Moreover, use of fluorouracil may also lead to side effects such as gastrointestinal dysfunction and enteric neurotoxicity.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4246

Market Taxonomy:

The global Fluorouracil (5FU) Market by type, is segmented into:

• Injectable
• Capsules
• Tablets
• By Route of Administration:
  • Parental
  • Oral
  • Others

• By Indication:
  • Colon and Rectal Cancer
  • Anal Cancer
  • Breast Cancer
  • Gastro-intestinal Cancer
  • Head and Neck Cancer
  • Thymic Cancer
  • Others

• By Region:
  • North America
  • Latent America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Regional Analysis:

North America is expected to witness significant growth in fluorouracil (5FU) market. The growth of the market is driven by high incidence of cancer in the region. For instance, according to NIH-National Cancer Institute, in 2018 was estimated that 1,735,350 new cases of cancer were diagnosed in United States. Different initiatives have been taken by governments as well as non-government associations. For instance, Pan America Health Organization (PAHO) is working in North America to lower the number of premature deaths caused by cancer to 25% by 2030.

Moreover, Europe is also expected to witness significant growth in fluorouracil (5FU) market, owing to cancer being the second leading cause of deaths and morbidity in the region.

Competitive Section:

Key players involved in global fluorouracil (5FU) market are Nantong Haier’s Pharmaceutical co. ltd, Jinghua Pharmaceutical Co., Ltd, DCS Pharma AG, Glaxo Smith Kline Pharmaceuticals Ltd, Dabur Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, and Dolder Ltd.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837